Genes expressed in mental illness and mood disorders

Abstract

The present invention relates to a composition comprising a plurality of cDNA molecules for use in methods of detecting changes in expression of genes encoding proteins that are associated with mental illnesses and which are differentially expressed in patients with mental illnesses, such as bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia. attention deficit hyperactive disorders, obsessive compulsive disorders, anxiety disorders or other related mood disorders. The composition and the cDNA molecules may be used in their entirety or in part as to diagnose. to stage, to treat. and/or to monitor the treatment of a subject with mental illness.

1 - 23 . (canceled) 
     
     
         24 . A method for treating mental illness comprising:
 obtaining a sample containing nucleic acid transcripts from a subject;   combining the sample with a composition comprising a plurality of cDNA molecules, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs:1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;   detecting the one or more hybridization complexes;   comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the intensity of each hybridization complex indicates differential expression of cDNAs in the sample;   identifying the subject to have a mental illness based on the differential expression of cDNAs in the sample; and   administering to the subject a treatment for the mental illness.   
     
     
         25 . A method for treating mental illness comprising:
 obtaining a sample containing nucleic acids from a subject;   combining the sample with an array comprising a plurality of cDNA molecules immobilized on a substrate, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs: 1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;   detecting the one or more hybridization complexes;   comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the intensity of each hybridization complex indicates differential expression of cDNAs in the sample;   identifying the subject to have a mental illness based on the differential expression of cDNAs in the sample; and   administering to the subject a treatment for the mental illness.   
     
     
         26 . The method of  claim 24  or  25 , wherein said plurality of cDNA molecules consists of SEQ ID NOs: 1-8, wherein one or more of SEQ ID NOs:1-8 may be substituted for by the complement of said cDNA molecule. 
     
     
         27 . The method of  claim 24  or  25 , wherein said plurality of cDNA molecules consists of SEQ ID NOs:1-15, wherein one or more of SEQ ID NOs:1-15 may be substituted for by the complement of said cDNA molecule. 
     
     
         28 . The method of  claim 25 , wherein said substrate is selected from the group consisting of a nylon membrane, a nitrocellulose membrane, a polypropylene support, a glass support and a silicon support. 
     
     
         29 . The method of  claim 24  or  25 , wherein the sample is blood or is obtained by separation from blood. 
     
     
         30 . The method of  claim 24  or  25 , wherein said nucleic acids are amplified prior to hybridization. 
     
     
         31 . The method of  claim 24  or  25 , wherein said differential expression is a downregulation of at least two-fold in said sample from said subject with a mental illness. 
     
     
         32 . The method of  claim 24  or  25 , wherein the mental illness is selected from the group consisting of bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, an attention deficit hyperactive disorder, an obsessive compulsive disorder, an anxiety disorder and a mood related disorder. 
     
     
         33 . A method of monitoring treatment for mental illness comprising
 obtaining a sample containing nucleic acids from a subject treated for mental illness;   combining the sample with a composition comprising a plurality of cDNA molecules, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs:1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;   detecting the one or more hybridization complexes;   comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the intensity of each hybridization complex indicates differential expression of cDNAs in the sample; and   altering treatment for the subject treated for mental illness when differential expression of cDNAs in the sample is detected.   
     
     
         34 . A method of monitoring treatment for mental illness comprising
 obtaining a sample containing nucleic acids from a subject treated for mental illness;   combining the sample with an array comprising a plurality of cDNA molecules immobilized on a substrate, wherein the plurality of cDNA molecules consists of two or more cDNA molecules selected from the group consisting of SEQ ID NOs:1-50, wherein one or more of SEQ ID NOs: 1-50 may be substituted for by the complement of said cDNA molecule, to form one or more hybridization complexes;   detecting the one or more hybridization complexes;   comparing the one or more hybridization complexes detected with those from a subject without a mental illness, wherein differences in the size and intensity of each hybridization complex indicates differential expression of cDNAs in the sample; and   altering treatment for the subject treated for mental illness when differential expression of cDNAs in the sample is detected.   
     
     
         35 . The method of  claim 33  or  34 , wherein said plurality of cDNA molecules consists of SEQ ID NOs: 1-8, wherein one or more of SEQ ID NOs:1-8 may be substituted for by the complement of said cDNA molecule. 
     
     
         36 . The method of  claim 33  or  34 , wherein the plurality of cDNA molecules consists of SEQ ID NOs:1-15, wherein one or more of SEQ ID NOs:1-15 may be substituted for by the complement of said cDNA molecule. 
     
     
         37 . The method of  claim 33  or  34 , wherein said plurality of cDNA molecules consists of SEQ ID NOs: 1-8, wherein one or more of SEQ ID NOs:1-8 may be substituted for by the complement of said cDNA molecule. 
     
     
         38 . The method of  claim 33  or  34 , wherein said plurality of cDNA molecules consists of SEQ ID NOs:1-15, wherein one or more of SEQ ID NOs:1-15 may be substituted for by the complement of said cDNA molecule. 
     
     
         39 . The method of  claim 34 , wherein the substrate is selected from the group consisting of a nylon membrane, a nitrocellulose membrane, a polypropylene support, a glass support and a silicon support. 
     
     
         40 . The method of  claim 33  or  34 , wherein the sample is blood or is obtained by separation from blood. 
     
     
         41 . The method of  claim 33  or  34 , wherein the nucleic acids are amplified prior to hybridization. 
     
     
         42 . The method of  claim 33  or  34 , wherein said differential expression is a downregulation of at least two-fold in said sample from said subject with a mental illness. 
     
     
         43 . The method of  claim 33  or  34 , wherein the mental illnesses is selected from the group consisting of bipolar I disorder, bipolar II disorder, unipolar disorder, schizophrenia, an attention deficit hyperactive disorder, an obsessive compulsive disorder, an anxiety disorder and a mood related disorder.